With many PBMs receiving scrutiny, smaller startups that bill themselves as more transparent are seeing interest from employers in the state and nationally.

In 2014, Caremark was accused of manipulating how drug costs were reported, prompting Aetna and SilverScript to submit false ...

In this final video of a three-part video series, Joshua Fredell, Pharm.D., senior vice president at CVS Caremark and a ...

A federal judge tripled damages against the pharmacy benefits manager after finding it encouraged inflated Medicare drug ...

Every Friday, GoLocalProv takes a look at who is rising and who is falling in Rhode Island and national politics, business, ...

Approved in June for people at high risk of HIV, Yeztugo was shown to be nearly 100% effective at preventing infection in ...

The owner of the U.S.' largest pharmacy benefit manager is declining to cover Gilead Sciences’ long-acting HIV prevention ...

Gov. Ned Lamont signed Public Act 25-167 into law July 30. Its aim is to implement the task force’s recommendations in an ...

A federal judge has ordered CVS Health's PBM Caremark to pay nearly $290 million after a whistleblower accused the business of overcharging Medicare on prescription drugs more than a decade ago.

CVS rejected coverage of Gilead's new HIV prevention drug Yeztugo, citing regulatory and financial factors, while facing nearly $290 million in Medicare overcharge penalties.

CVS Health stock offers an above-average dividend yield for investors seeking income and it's run up to a new buy point.